Neogen Corp income statement

In fiscal 2026, Neogen Corp reported revenue of $870m, down 2.7% on the year before, operating income of −$21.6m (a -2.5% margin) and net income of −$7.9m, or −$0.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Neogen Corp: income statement, annual
Fiscal year	2010May 2010	2011May 2011	2012May 2012	2013May 2013	2014May 2014	2015May 2015	2016May 2016	2017May 2017	2018May 2018	2019May 2019	2020May 2020	2021May 2021	2022May 2022	2023May 2023	2024May 2024	2025May 2025	2026May 2026	LTMAug 2026
Revenue	141	173	184	208	247	283	321	358	398	414	418	468	527	822	924	895	870	884
Cost of revenue	—	85	92	98	125	143	168	190	212	222	222	253	284	416	460	473	462	465
Gross profit	73	88	92	109	123	140	153	169	186	192	196	215	243	406	464	421	409	419
Research and development	6	7	7	8	8	10	10	10	11	13	15	16	17	26	23	21	18	20
Selling and marketing	26	30	35	41	46	52	58	59	67	70	70	73	85	141	183	184	167	163
General and administrative	13	15	17	20	24	25	29	34	38	41	44	51	83	201	200	218	245	244
Operating income	27	36	34	41	43	53	56	65	70	68	68	74	59	38	59	−1,061	−22	−7
Interest expense	—	—	—	—	—	—	—	—	—	—	—	—	—	27	42	38	24	—
Income before tax	27	35	34	41	43	52	56	67	73	73	72	75	60	−22	−14	−1,133	−9	−68
Income tax	10	12	11	14	15	19	19	23	10	13	13	14	12	1	−5	−41	−1	−12
Net income	18	23	23	27	28	34	37	44	63	60	59	61	48	−23	−9	−1,092	−8	−56
Diluted EPS	$0.19	$0.24	$0.23	$0.28	$0.29	$0.34	$0.36	$0.43	$0.60	$0.57	$0.56	$0.57	$0.45	−$0.12	−$0.04	−$5.03	−$0.04	−$0.26
Diluted shares (average)	92m	95m	96m	97m	99m	100m	101m	102m	104m	105m	106m	107m	108m	189m	217m	217m	218m	218m
EBITDA	31	41	40	48	53	64	69	80	87	86	86	95	82	126	175	−942	95	109

US$ millions unless shown otherwise. Fiscal quarters.

Neogen Corp: income statement, quarterly
Quarter	2025 Q2Nov 2024	2025 Q3Feb 2025	2025 Q4May 2025	2026 Q1Aug 2025	2026 Q2Nov 2025	2026 Q3Feb 2026	2026 Q4May 2026	2027 Q1Aug 2026
Revenue	231	221	226	209	225	211	225	223
Cost of revenue	118	111	133	114	118	112	118	117
Gross profit	113	110	93	95	107	99	108	106
Research and development	5	5	6	5	5	4	5	7
Selling and marketing	47	45	47	45	42	38	41	42
General and administrative	58	56	53	61	65	60	59	59
Operating income	−457	5	−611	−16	−5	−3	3	−2
Income before tax	−477	−10	−631	44	−20	−20	−12	−15
Income tax	−20	1	−19	8	−4	−3	−1	−3
Net income	−456	−11	−612	36	−16	−17	−11	−12
Diluted EPS	−$2.10	−$0.05	−$2.82	$0.17	−$0.07	−$0.08	−$0.06	−$0.05
EBITDA	−427	35	−581	13	24	26	33	27

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: INSP vs NEOG NEOG vs VREX ATEC vs NEOG

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Neogen Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Neogen Corp.